Metabolic Disorders
The effect of adjuvant aromatase inhibitors on BMD in women with breast cancer
Lancet Oncol. 2014 Apr;15(4):474-82. doi: 10.1016/S1470-2045(14)70035-X. Epub 2014 Mar 11

Metabolic Disorders
Better clinicoradiological results at 3 years with SpineJack vertebral augmentation vs BPK for VCFs
Osteoporos Int. 2019 Mar;30(3):637-645. doi: 10.1007/s00198-018-4773-5

Metabolic Disorders
Significant reduction in 6-year fragility fracture risk with zoledronate vs placebo for osteopenia
N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082

Arthroplasty
Periprosthetic bone loss post-total hip arthroplasty mitigated by bisphosphonate therapy
J Orthop Surg Res. 2018 Sep 4;13(1):225. doi: 10.1186/s13018-018-0918-7

Metabolic Disorders
Adherence to weekly oral BP therapy versus quarterly IV BP therapy at varying health literacy level
J Bone Miner Metab. 2018 Sep;36(5):589-595. doi: 10.1007/s00774-017-0867-y

Metabolic Disorders
Incidence of falls reduced following balance training in patients with osteoporosis
J Rehabil Med. 2018 Jul 17;50(7):577-581. doi: 10.2340/16501977-2334

Metabolic Disorders
Romosozumab versus placebo, alendronate, and teriparatide for postmenopausal osteoporosis
Climacteric. 2018 Apr;21(2):189-195

Metabolic Disorders
Larger BMD gains in osteoporosis patients transitioning to denosumab versus other active controls
Expert Opin Drug Saf. 2018 Apr;17(4):413-428

Metabolic Disorders
Zoledronic Acid, alendronate, and risedronate reduce vertebral, nonvertebral, and hip fracture
Osteoporos Int. 2016 Nov;27(11):3289-3300

Metabolic Disorders
AAOS2018: Abaloparatide 80ug daily reduces rate of major NVFs in osteoporotic postmenopausal women

General Orthopaedics
Lower incidence of vertebral fracture with romosozumab vs placebo for osteoporosis
N Engl J Med. 2016 Oct 20;375(16):1532-1543

Metabolic Disorders
The effect of eldecalcitol on balence and strength in women with osteoporosis
J Bone Miner Metab. 2016 Sep;34(5):547-54

Metabolic Disorders
Immediate effects on bone metabolism biomarkers noted with resistance training and walking
BMC Musculoskelet Disord. 2016 Jun 8;17(1):254

Metabolic Disorders
Efficacy of zoledronic acid following PLIF in patients with osteoporosis
Osteoporos Int. 2016 Apr;27(4):1469-76

Metabolic Disorders
Efficacy of combined teriparatide & denosumab vs. single-drug treatment for osteoporosis
J Clin Endocrinol Metab. 2016 May;101(5):2023-30

Metabolic Disorders
Network meta-analysis of anti-osteoporosis therapies for oral glucocorticoid users
Osteoporos Int. 2016 Jun;27(6):1989-98

Metabolic Disorders
Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates
J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70

Metabolic Disorders
Combination therapy improves site-specific BMD vs. teriparatide & denosumab monotherapies
J Clin Densitom. 2016 Jul-Sep;19(3):346-51

Metabolic Disorders
No effect of GLP-1 receptor agonists on fracture incidence in type 2 diabetes treatment
J Diabetes. 2014 May;6(3):260-6. doi: 10.1111/1753-0407.12102. Epub 2013 Nov 22

Metabolic Disorders
Denosumab increases BMD and reduces bone turnover vs monthly oral bisphosphonate
Osteoporos Int. 2014 Jul;25(7):1953-61. doi: 10.1007/s00198-014-2692-7. Epub 2014 Mar 28.